These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 31327828)

  • 1. Hyperprogressive Disease in Lung Cancer with Transformation of Adenocarcinoma to Small-cell Carcinoma during Pembrolizumab Therapy.
    Okeya K; Kawagishi Y; Muranaka E; Izumida T; Tsuji H; Takeda S
    Intern Med; 2019 Nov; 58(22):3295-3298. PubMed ID: 31327828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case of pulmonary adenocarcinoma showing rapid progression of peritoneal dissemination after immune checkpoint inhibitor therapy.
    Shinozaki T; Iwami E; Ikemura S; Matsuzaki T; Nakajima T; Hashimoto K; Terashima T
    BMC Cancer; 2018 May; 18(1):620. PubMed ID: 29855288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psuedoprogression mimicking hyperprogressive disease after pembrolizumab treatment in a patient with lung cancer.
    Hashimoto K; Kaira K; Kawasaki T; Yamaguchi O; Kagamu H
    Lung Cancer; 2020 Jan; 139():221-223. PubMed ID: 31806361
    [No Abstract]   [Full Text] [Related]  

  • 4. Histologic transformation of lung cancer during pembrolizumab therapy: A case report.
    Si X; You Y; Zhang X; Wang H; Wang M; Zhang L
    Thorac Cancer; 2020 Mar; 11(3):793-796. PubMed ID: 31944570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperprogression after first dose of immunotherapy in a patient with radioresistant metastasis from nonsmall cell lung cancer.
    Bosch-Barrera J; Oliva E; Sais E; Vásquez CA; Roselló A; Menéndez JA
    Anticancer Drugs; 2019 Nov; 30(10):1067-1070. PubMed ID: 31567311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bilateral lung cancer showing various responses to immune checkpoint inhibitors: A case report.
    Kodama H; Ibe T; Inoue R; Shimada T; Ishii H; Hamamoto Y
    Cancer Rep (Hoboken); 2020 Oct; 3(5):e1272. PubMed ID: 32783372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature.
    Feng D; Guan Y; Liu M; He S; Zhao W; Yin B; Liang J; Li Y; Wang J
    Front Immunol; 2021; 12():608292. PubMed ID: 34135884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dramatic, significant metabolic response to a one-time pembrolizumab treatment following a relapse of pre-existing organizing pneumonia in a patient with advanced non-small cell lung cancer: A case report.
    Kato M; Mori M; Miura K; Asao T; Motomura H; Nishino K; Ko R; Koyama R; Hayashi T; Takahashi K
    Thorac Cancer; 2021 Nov; 12(22):3076-3079. PubMed ID: 34617405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report.
    Sugano T; Seike M; Funasaka Y; Yoshida M; Takayama R; Okamura K; Nakanishi A; Tanaka T; Takeuchi S; Noro R; Minegishi Y; Kubota K; Saeki H; Gemma A
    J Immunother Cancer; 2019 Feb; 7(1):59. PubMed ID: 30813943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possible Pseudo-progression of Non-small Cell Lung Carcinoma in a Patient With Clinical Hyper-progression Associated With Trousseau Syndrome Who Was Treated With Pembrolizumab: A Case Report.
    Shionoya Y; Hirohashi Y; Takahashi H; Hashimoto M; Nishiyama K; Takakuwa Y; Nakatsugawa M; Kubo T; Kanaseki T; Tsukahara T; Torigoe T
    Anticancer Res; 2021 Jul; 41(7):3699-3706. PubMed ID: 34230169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cholestatic Liver Injury Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma.
    Kurokawa K; Hara M; Iwakami SI; Genda T; Iwakami N; Miyashita Y; Fujioka M; Sasaki S; Takahashi K
    Intern Med; 2019; 58(22):3283-3287. PubMed ID: 31735738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction model for hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitors.
    Choi YJ; Kim T; Kim EY; Lee SH; Kwon DS; Chang YS
    Thorac Cancer; 2020 Oct; 11(10):2793-2803. PubMed ID: 32779394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Advances in Hyperprogressive Disease in Patients 
with Advanced Non-small Cell Lung Cancer Treated with Immunotherapy].
    Yao S; Shi K; Zhang Y
    Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):271-278. PubMed ID: 33910275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transformation of lung adenocarcinoma to small cell lung carcinoma in the setting of tyrosine kinase inhibitor therapy: Cytological approach of a clinically challenging phenomenon.
    El Hussein S; Khader SN
    Diagn Cytopathol; 2019 Aug; 47(8):845-850. PubMed ID: 31017747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pericardial tamponade during pembrolizumab treatment in a patient with advanced lung adenocarcinoma: A case report and review of the literature.
    Harada K; Ogasawara M; Shido A; Meno A; Oda S; Yoshida S; Yoshida S; Yoshikawa A; Ebata K; Abiko S; Kawagishi N; Sano I; Oda H; Miyagishima T
    Thorac Cancer; 2020 May; 11(5):1350-1353. PubMed ID: 32181993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyper-progressive disease in a patient with advanced non-small cell lung cancer on immune checkpoint inhibitor therapy: A case report and literature review.
    Zhang D; Zhang Y; Huang Y; Kong L; Yu J
    Lung Cancer; 2020 Jan; 139():18-21. PubMed ID: 31704279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperprogressive disease after treatment with pembrolizumab in lung adenocarcinoma: An autopsy case study.
    Tanaka Y; Matsubara O; Asada K; Muramatsu A; Suzuki M; Shirai T
    Respir Med Case Rep; 2019; 28():100885. PubMed ID: 31249779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transformation to small cell lung cancer as a mechanism of resistance to immunotherapy in non-small cell lung cancer.
    Bar J; Ofek E; Barshack I; Gottfried T; Zadok O; Kamer I; Urban D; Perelman M; Onn A
    Lung Cancer; 2019 Dec; 138():109-115. PubMed ID: 31683093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuropsychiatric Immune-related Adverse Events Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma and Systemic Lupus Erythematosus.
    Jono M; Kinehara Y; Utsu Y; Tamura Y; Koseto M; Murakami T; Uota A; Ninomiya R; Komo S; Sumitani S; Sato B; Kasayama S; Tachibana I
    Intern Med; 2020 Feb; 59(4):569-572. PubMed ID: 31666468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sarcoid-like reaction of the extrathoracic lymph node in a patient with lung adenocarcinoma treated with pembrolizumab.
    Takamori S; Furubayashi N; Taguchi K; Matsubara T; Fujishita T; Ito K; Yamaguchi M; Toyozawa R; Seto T; Negishi T; Nakamura M; Okamoto T
    Thorac Cancer; 2021 Jul; 12(14):2122-2125. PubMed ID: 34002950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.